Sildenafil (Viagra) is a candidate drug for Alzheimer’s disease

The hypothesis that accumulation of amyloid‐beta protein and consequent tau pathology represents the main cause of Alzheimer’s disease (AD) has dominated the field for more than 2 decades; yet, anti‐tau or anti‐amyloid selective drug discovery approaches have lack of clinical benefits for AD patients. We posited that systematic identification of underlying AD‐related endophenotype modules shared by amyloid and tau may provide a foundation for generating predictive models to characterize pathogenesis and therapeutic development for AD.